gretel
16 Nov 2016
New interview with CEO Gormally comes across extremely well.Certainly lots to look forward to. And more optimism about the $2m Chinese sale coming through this quarter, which will be great news if so:[link]
gretel
15 Nov 2016
Q3 conference call transcript AKR definitively say that Q4 "is expected to be profitable", and that the rest of the $2.5m Chinese order will be received this quarter. So these things had better happen.I suspect when/if they announce the receipt of the Chinese cash the share price may go a fair bit higher.Here's a link to the conference call for the record:[link]
gretel
14 Nov 2016
Good RNS today in terms of revenue improvements and major cost reductions:[link] cash in hand, with $2m due from Novatek in the next month (before 31st December), so hopefully this will run smoothly.The concluding outlook reads extremely well - notably re profitability next year:"OutlookAkers Bio moves into the final quarter of 2016 with excellent momentum in domestic sales of our flagship rapid test for HIT and with the remaining $2,000,000 due under the Novotek order for products in China which we expect to be fulfilled in the fourth quarter. There is also evidence of further demand for Akers Wellness™ products which are expected to produce additional sales in the remaining months of the year. The combination of these growing product sales and a leaner cost base is expected to enable Akers Bio to trade profitably both in the final quarter and, more significantly, in 2017."
gretel
10 Nov 2016
RNS : patent grant [link] breath test for diabetics seems like a potentially huge winner imho, backed up by the comment in the RNS: "The technology has a large number of potential mass-market applications, including within health and wellness, but in particular, we believe the ability to help Type 1 and some Type 2 diabetics monitor their ketone levels in a non-invasive, convenient format will be a significant advancement in the management of a disease that affects hundreds of millions of people worldwide," added Dr. Akers."
gretel
22 Aug 2016
Good news and US price rising today Nice start in the USA this afternoon - up to $3.68, i.e around 283p in UK terms. Great to see two pieces of good news in the last week:The Chubeworks settlement is particularly good news since the entire $1.25m had already been written off, whereas now AKR will receive a very useful $500k of cash plus $750k of stock for resale:[link] also the successful results of the Oxichek test study:[link]
gretel
30 Jun 2016
World's first rapid Chlamydia test..... Wow - AKR announce the "highly successful" completion of a trial for "the first rapid test for Chlamydia diagnosis using a finger stick blood sample":[link] the potential for this test and the potential global take-up....There's certainly nothing in the share price for this on a mere £9m m/cap.
gretel
28 Jun 2016
Movied up fast in the USA Up to $2.54 in the USA at the close last night, i.e around 190p at current rates, compared to the current 160p share price in the UK.Brexit is at least good for foreign-denominated stocks in translation terms given the weak pound!Terrific volumes too in the USA with 2.4m shares traded yesterday.
gretel
27 Jun 2016
Major agreement with Cardinal Health Nice - a first distribution agreement for OxiChek is with the mighty Cardinal Health (via Aero-Med). And some orders already placed:[link] DelMastro, CEO of Aero-Med added, "Aero-Med recognizes the enormous market potential for products within the health and wellness sector so we are delighted to be incorporating OxiChek into our sales offering. Having personally observed the positive customer reaction to OxiChek at conventions in recent months, I am optimistic that there is strong potential for this product."
gretel
22 Jun 2016
Finncap very positive "Akers’ HIT diagnostic key to short term growth, says finnCap16:19 17 Jun 2016 House broker finnCap has reintroduced estimates for Akers Biosciences Inc (LON:AKR) and is predicting a steep uplift in sales.The broker unveiled a forecast of US$5.6mln in revenues for 2016, up from US$2.1mln in 2015, with 88% growth in the flagship PIFA Heparin/PF4 rapid assay products.Mark Brewer, analyst at broker finnCap says, the medical diagnostic maker, has the potential for stronger growth in the second half of the year “through the launch of new products”.“The core and the key to driving growth in the short term is how well they do with the heparin-induced thrombocytopenia diagnostic” he adds.Brewer’s note inspired a 10% rise in Aker’s shares. The stock has gained 73% since the start of 2016.[link]
RichardLY
05 Nov 2015
Re: Hugely imprtant new today But SP showing something different?
gretel
04 Nov 2015
Hugely imprtant new today Great RNS - the Chinese FDA have approved "for medical use throughout Mainland China the Company's flagship rapid tests for allergic reactions associated with the widely used blood-thinner, heparin."With Novotek already in place as the distributor, this is excellent news for a mere £9m m/cap company. And Akers' test is the first and only such test of its kind in China.Consider the size of Novotek:"NovoTek Therapeutics Inc. is a vital part of NovoTek Group, and is in charge of all international business. To date, NovoTek Group has grown to seven subsidiary companies focused on pharmaceutical marketing, medical and IVD products marketing, and contract research services. NovoTek has its own preclinical research facility, clinical trial and regulatory teams, and more than 600 sales representatives (500 for pharmaceuticals and 100 for medical devices) across China. NovoTek has more than 800 employees and more than 10 local branches nationwide. www.novotekchina.com "
gretel
06 Oct 2015
RNS today re commercialisation ....of the new wellness tests:[link] Biosciences, Inc.Commercializes New App-Enabled Tests for Health and Wellness Industry and ConsumersAkers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"
, a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, announces that all development specifications have been finalized and production has commenced for its two transformational breath tests designed for the health and wellness industry and consumers.Akers Bio is launching the BreathScan OxiChek™ ("OxiChek" and BreathScan KetoChek™ ("KetoChek" tests this week at the Supply Side West conference in Las Vegas, Nevada. The conference focuses on dietary supplements and sports nutrition, two key markets for these new products.OxiChek is the first disposable breath test to rapidly determine levels of oxidative stress (free radicals) in the body. OxiChek measures the most abundant free radicals including superoxides, hydrogen peroxide and aldehydes - unlike some pre-existing devices which measure only one. Frequent use of OxiChek may help consumers and professional clients manage and adhere to their regimen of nutritional supplementation for management of oxidative stress, which is implicated in many diseases, including cardiac, cancer and arthritic diseases.KetoChek, and the Company's non-quantitative version, METRON®, are the only disposable breath-based diagnostic devices that rapidly determine if the subject is in the optimal fat-burning state for weight loss, known as ketosis. Achieving a state of ketosis - as indicated by the measure of breath ketones - is a goal of many individuals following low carbohydrate diets. KetoChek is a simple, non-invasive test to identify, track and quantitatively monitor breath ketones for individuals interested in maximizing weight loss....."The response to the Akers Wellness products has been overwhelmingly positive," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman. "We launched our first product, METRON®, into this market last month, including through the Amazon marketplace. Now, the Company is expanding its market reach through our efforts at Supply Side West, targeting multi-level marketing companies in the nutraceutical business, fitness and weight loss centers, chiropractors, and anti-aging medicine physicians. The Company is aggressively seeking distribution into these market segments," continued Dr. Akers. "We believe that consumers are increasingly looking for personalized health, and that the BreathScan platform will provide the footprint for the Company to enter into the new era of digital medicine. Our new health and wellness products are poised to make an impact now as we commence production and will begin shipping this quarter....."
gretel
05 Oct 2015
Billion dollar opportunity [link] on 1 Oct 2015Raymond Akers, chief executive of Akers Biosciences (LON:AKR), reckons the global heparin-induced thrombocytopenia (HIT) test industry is not far away from being valued as a US$1bn market.Akers is a front runner in the space and has distribution for its own HIT test in every major diagnostic market after inking agreements for India, Germany, Italy and Scandinavia.Millions of patients are exposed to heparin around the world each year and between 1% and 5% of those patients receive a HIT diagnosis.The test is the only US and EU cleared rapid test to detect a potentially fatal allergy to the widely used blood thinner, heparin.That allergy reverses the effect of heparin and turns it into a clotting agent, which is clearly very dangerous."
Chard Nick
18 Aug 2015
When Will This Company... ever make a profit?It's taking ages!One for the bottom of the bottom drawer.Yawn
gretel
12 May 2015
News : new products in the USA In particular: "The Company is in discussions with a number of strategic partners specializing in the health and wellness industry with regards to the commercialization of OxiChek™, KetoChek™, and BreathScan Lync™[link] "Akers Biosciences Introduces New Rapid Breath Ketone and Oxidative Stress Tests to the Health and Wellness Industry Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company", a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, introduced two new breath tests to the U.S. market from the Company's Akers Wellness division at the World Congress on Anti-Aging Medicine in Hollywood, Florida, USA last week. etc"
